

# ACS NLCRT Lung Cancer Biomarker Testing ECHO Year 3

## Post Session 3: Recap & Resources

This document compiles some of the key resources mentioned during **Session 3: Choice of Panel, Interpretation of Results, and Next Steps**. To review all publications, articles, or commentaries mentioned, we recommend reviewing the presentation recording and PowerPoint presentation.

All slides and recordings can be found [here](#).

### CASE PRESENTATION SUMMARY & FEEDBACK

- Case Summary and Feedback [Link](#)

### HIGHLIGHTS OF SESSION RESOURCES

#### Biomarker Panel, Interpretation, and Next Steps

- Economic Impact of NGS vs. Single-Gene Testing to Detect Genomic Alterations in Metastatic NSCLC Using a Decision Analytic Model [Link](#)
- Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors [Link](#)
- High-Resolution Characterization of Sequence Signatures due to Non-Random Cleavage of Cell-Free DNA [Link](#)
- Identification of the Transforming EML4–ALK Fusion Gene in Non-Small-Cell Lung Cancer [Link](#)
- IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIa non-small cell lung cancer (NSCLC) [Link](#)
- Liquid Biopsy for Advanced NSCLC: A Consensus Statement ISALC [Link](#)
- Circulating tumor DNA analysis for tumor diagnosis [Link](#)
- Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged NSCLC [Link](#)
- STK11/LKBI Mutation & PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma [Link](#)
- Ti3C2 MXene Mediated Prussian Blue in situ Hybridization and electrochemical Signal Amplification for the Detection of Exosomes [Link](#)
- Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer [Link](#)
- Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer [Link](#)

#### Testing & Treatment for Advanced Stage Non-Small Cell Lung Cancer (NSCLC)

- Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer (ADAURA Trial) [Link](#)

#### Practice guidelines:

- IASLC Global Molecular Database for Thoracic Malignancies: Call for Data [Link](#)
- Molecular testing guidelines for treatment with targeted Tyrosine Kinase Inhibitors [Link](#)
- NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023 [Link](#)

### TOOLS/RESOURCE OF POTENTIAL INTEREST

- Free CME/CNE - Interpreting cancer biomarker testing - When is additional testing needed? (jax.org) [Link](#)